Key Drivers
- Strong Cash Flow
- High Intangible Assets
- Adequate Liquidity
AIAI Summary
ZBH is an execution-dependent transformation story: its 4% organic growth and strong free cash flow support the downside, but investors should wait for robotics, digital platforms, and commercial restructuring to translate into adjusted EPS growth and margin/share gains before treating the valuation as compelling.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Cash Flow
- •High Intangible Assets
- •Adequate Liquidity
ZBH delivers strong cash flow and stable margins, but elevated leverage, declining liquidity, and intangible-heavy assets warrant caution at its premium valuation.
Price Behavior
Key Price Behavior Insights:
- •Recent rebound failed
- •Support buyers emerged
- •Resistance remains firm
ZBH remains mildly bearish over the last month, with support at $92.44–$93.49 and a sustained break above $99.50 needed to improve momentum.
Rebounded from $92.44 to $98.41 before quickly retreating
Sentiment & News
Key News Insights:
- •Sales Momentum
- •Leadership Transformation
- •Earnings Risks
Zimmer Biomet shows improving sales momentum and transformation progress, but investors should weigh lagging earnings, debt, and competitive risks.
The news is cautiously positive for ZBH, with growth catalysts tempered by profitability and balance-sheet concerns
Similar Companies in Healthcare
Other companies in the same sector with AI ratings